Peer-influenced content. Sources you trust. No registration required. This is HCN.
Retina Today
Genetic testing identifies causative variants in approximately 65% to 70% of suspected inherited retinal disease cases and may shorten diagnostic delays. Advances in sequencing technologies and expanding testing access continue to shape retinal disease evaluation and counseling.
Medical Genetics August 24th 2026
MDLinx
Pediatric hearing loss care has shifted from physiologic detection and rehabilitation toward genetic diagnosis, prognostic counseling, and emerging targeted therapies. Advances in screening, cochlear implantation, and genetic testing have expanded etiologic evaluation, while therapeutic applications remain in early development.
Audiology August 13th 2026
The American Journal of Respiratory and Critical Care Medicine (AJRCCM)
The American Thoracic Society updated guidance for childhood interstitial lung disease in infants, emphasizing genetic testing, chest imaging, biopsy indications, and transplant referral. Recommendations formalize evaluation priorities for rare pediatric lung disorders.
Medical Genetics August 13th 2026
News Medical
A genome-wide analysis of more than 2.5 million adults identified 26 genetic regions associated with fibromyalgia risk. The findings support a neurologic biological basis for the condition, though they do not establish causality or create a diagnostic test.
Medical Genetics August 5th 2026
Medical Xpress
Analysis of genetic testing data from nearly 180,000 individuals with autism suggests that Phelan-McDermid syndrome may affect approximately 1 in 7,300 people. The findings indicate the condition may be substantially more common than previously estimated and highlight ongoing diagnostic gaps.
Adolescent Medicine July 27th 2026
Medical Professionals Reference (MPR)
The FDA expanded approval of the CRISPR-based gene therapy Casgevy to include patients as young as 2 years with sickle cell disease or transfusion-dependent beta thalassemia. The decision was supported by pediatric phase 3 data demonstrating sustained reductions in disease burden.
Hematology/Oncology July 27th 2026